Transformative Assets, Engineered to Succeed
Adagene’s purpose-built technology platforms have generated a pipeline of potential first or best in class therapeutic assets with unique MOAs.
- ADG106: Our lead NEObody™ program is a first-in-class, safe and potent agonist for CD137 that is being evaluated in patients with advanced/metastatic solid tumors.
- ADG126: Our lead SAFEbody™ program targets CTLA4 and has been shown in preclinical studies to be safer, potent and more durable than a commonly used CTLA4 cancer therapy.
- ADG116: Our second NEObody program, which targets a unique epitope of CTLA4, is being evaluated in patients with advanced/metastatic solid tumors and/or relapsed/refractory non-Hodgkin’s lymphoma.
Global partnerships and investments attest to the strong science underlying our pipeline and its potential to produce novel single-agent and combination therapies.
1 NEO, SAFE and POWER refer to the NEObodyTM, SAFEbodyTM and POWERbodyTM respectively
* The ADG104 Phase Ib/II clinical trial is conducted by our partner, Sanjin